Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Procter & Gamble

Exxon Mobil

On CNBC's "The Exchange," Jamie Cox of Harris Financial Group and Charles Bobrinskoy of Ariel Investment spoke about stocks they like in the current market environment.

Analysts Share Stocks They Would Buy In This Environment: Exxon Mobil, P&G And More

Becton, Dickinson and Co.

Ford Motor Company

Fiat Chrysler

General Motors

Johnson & Johnson

Medtronic

NuVasive

Royal Philips

ResMed

Smith & Nephew

Stryker

Tesla

Wright Medical Group

Some of the biggest medical device companies' stocks have dropped to attractive prices due to the current COVID-19 pandemic.

Can Medical Device Stocks Help Rebuild Your Portfolio?

Investors continue to be optimistic about Zimmer Biomet (ZBH) on its strong segmental and international results in the fourth quarter of 2019.

Here's Why You Should Add Zimmer Biomet to Your Portfolio Now

Zimmer Biomet (ZBH) solidifies its foothold in the emerging markets on strong operational and sales performance.

Zimmer Biomet Grows on Strong Emerging Market, Innovation

ZBH vs. MDT: Which Stock Is the Better Value Option?

ZBH or MDT: Which Is the Better Value Stock Right Now?

NVIDIA

Robotics and AI make rapid advancement in the field of healthcare. Here are five stocks that you can bet on.

Robotics & AI Make Inroads in HealthCare: Stocks to Benefit

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Why Is Zimmer (ZBH) Down 12.5% Since Last Earnings Report?

Abbott Labs

Baxter

Boston Scientific

Hill-Rom Hlds

Intuitive Surgical

Perrigo

Medical Products Industry Outlook: Growth Prospects Bright

Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.

Here's Why You Should Add Zimmer (ZBH) to Your Portfolio

Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zimmer Biomet (ZBH) Is Up 0.07% in One Week: What You Should Know

Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q4 2019 Results - Earnings Call Transcript

The company's hip and knee replacement products continue to enjoy solid demand.

How Zimmer Biomet Holdings Beat Expectations in Q4

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.

Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?

Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.

Zimmer Biomet Rides on Product Launches Despite Pricing Woes

Zimmer Biomet Is Looking Healthy Again

Zimmer Biomet: Leaving Problems Behind

Investors continue to be optimistic about Zimmer (ZBH) on its stellar segmental performance in Q3.

Here's Why You Should Hold on to Zimmer (ZBH) Stock for Now

Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.

Zimmer Biomet Hits New 52-Week High: What's Driving It?

Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.

Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes

Zimmer (ZBH) Up 3.6% Since Last Earnings Report: Can It Continue?

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.

Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?

Zimmer (ZBH) is likely to maintain the current high on a number of favorable factors.

Zimmer (ZBH) Scales 52-Week High: What's Driving the Stock?

Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q3 2019 Results - Earnings Call Transcript

News for Zimmer Biomet Hlds Stock (ZBH)